While overstimulation of the CB1 receptor may lead to symptoms such as high blood pressure and abnormally high cholesterol levels, CBD is a CB1 antagonist, so it is not likely to cause such issues. Furthermore, the World Health Organization has recently issued a global report on CBD, claiming that it has a good safety profile and minimal adverse public health effects.
To briefly review, the endocannabinoid system (ECS) is a group of specialized fatty acid-based signaling chemicals (think “keys”), their receptors (think “locks”), and the metabolic enzymes that produce and break them down. These endocannabinoid chemical signals act on similar brain and immune cell receptors (CB1 and CB2) using the active compounds found in cannabis – cannabidiol (CBD), and Δ9-tetrahydrocannabinol (THC).
When the endocannabinoid system becomes dysregulated, it often becomes overactive and too much fat is being stored, particularly in the intra-abdominal tissue. Cannabidiol is known to regulate the endocannabinoid system as it can restore balance in both directions. Therefore, the study concludes that, along with lifestyle changes cannabis could be a means of fighting obesity.